INT274273

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 5
Disease Relevance 4.39
Pain Relevance 0.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

NARFL (Homo sapiens)
Pain Link Frequency Relevance Heat
beta blocker 43 93.40 High High
Inflammation 4 83.60 Quite High
Onset of action 2 63.68 Quite High
corticosteroid 2 18.60 Low Low
headache 22 5.00 Very Low Very Low Very Low
agonist 13 5.00 Very Low Very Low Very Low
eye pain 12 5.00 Very Low Very Low Very Low
Angina 9 5.00 Very Low Very Low Very Low
Pain 6 5.00 Very Low Very Low Very Low
backache 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Ocular Hypertension 635 100.00 Very High Very High Very High
Glaucoma 176 99.60 Very High Very High Very High
Low Tension Glaucoma 2 94.76 High High
Uveitis 8 91.92 High High
Conjunctivitis 36 87.12 High High
INFLAMMATION 4 83.60 Quite High
Hypotension 50 76.28 Quite High
Infection 2 71.44 Quite High
Herpes Simplex Virus Infection 4 71.04 Quite High
Eczema 2 65.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The fixed combination dorzolamide–timolol was less effective in reducng IOP (?
Regulation (effective) of Gene_expression (reducng) of IOP associated with ocular hypertension
1) Confidence 0.10 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993108 Disease Relevance 0.67 Pain Relevance 0.08
The mean difference in IOP reduction between the 2 treatment groups was 1.0 mmHg, a 95% CI of 0.31 to 1.69 (P = 0.005) showing statistically significantly more favorable results in the latanoprost–timolol group.43
Regulation (difference) of Gene_expression (reduction) of IOP associated with ocular hypertension
2) Confidence 0.10 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993108 Disease Relevance 0.68 Pain Relevance 0
The efficacy of the dorzolamide–timolol fixed combination (dorzolamide–timolol dosed twice daily) was also found to be comparable to the IOP-lowering effect of its individual components when administered concomitantly (dorzolamide hydrochloride 2% 3 times daily plus timolol maleate 0.5% twice daily).11,36,37 A statistically significant additional IOP reduction was observed in 1study in which the dorzolamide–timolol fixed combination therapy was used as a replacement therapy for patients who were being treated with both a beta blocker and dorzolamide.36
Regulation (effect) of Gene_expression (reduction) of IOP associated with beta blocker and ocular hypertension
3) Confidence 0.10 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2993108 Disease Relevance 0.41 Pain Relevance 0.05
Based on these criteria for evaluation, bimatoprost is highly effective for IOP reduction, has excellent systemic safety profiles, and is easy to use with once-daily schedule.
Regulation (effective) of Gene_expression (reduction) of IOP associated with ocular hypertension
4) Confidence 0.06 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701126 Disease Relevance 0.61 Pain Relevance 0
Because of its similarity with latanoprost, bimatoprost is expected to be effective in IOP reduction in these glaucoma subtypes.
Regulation (effective) of Gene_expression (reduction) of IOP associated with glaucoma and ocular hypertension
5) Confidence 0.06 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701126 Disease Relevance 2.02 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox